IL107134A - Pharmaceutical compositions for the treatment of parkinson's disease - Google Patents

Pharmaceutical compositions for the treatment of parkinson's disease

Info

Publication number
IL107134A
IL107134A IL107134A IL10713493A IL107134A IL 107134 A IL107134 A IL 107134A IL 107134 A IL107134 A IL 107134A IL 10713493 A IL10713493 A IL 10713493A IL 107134 A IL107134 A IL 107134A
Authority
IL
Israel
Prior art keywords
histamine
parkinson
disease
receptor antagonist
famotidine
Prior art date
Application number
IL107134A
Other languages
English (en)
Other versions
IL107134A0 (en
Original Assignee
Kaminski Ram
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaminski Ram filed Critical Kaminski Ram
Publication of IL107134A0 publication Critical patent/IL107134A0/xx
Publication of IL107134A publication Critical patent/IL107134A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL107134A 1992-09-30 1993-09-28 Pharmaceutical compositions for the treatment of parkinson's disease IL107134A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/954,258 US5352688A (en) 1991-02-14 1992-09-30 Methods for the treatment of bradyphrenia in parkinson's disease

Publications (2)

Publication Number Publication Date
IL107134A0 IL107134A0 (en) 1993-12-28
IL107134A true IL107134A (en) 1998-02-22

Family

ID=25495171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL107134A IL107134A (en) 1992-09-30 1993-09-28 Pharmaceutical compositions for the treatment of parkinson's disease

Country Status (9)

Country Link
US (2) US5352688A (fr)
EP (1) EP0665749B1 (fr)
AT (1) ATE190840T1 (fr)
AU (1) AU688739B2 (fr)
CA (1) CA2145521A1 (fr)
DE (1) DE69328186T2 (fr)
DK (1) DK0665749T3 (fr)
IL (1) IL107134A (fr)
WO (1) WO1994007490A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
CA2198457A1 (fr) * 1994-08-30 1996-03-07 Koichi Kojima Derives d'isoxazole
CA2237384A1 (fr) * 1995-11-13 1997-05-22 The Albany Medical College Composes analgesiques et leurs utilisations
EP1003554B1 (fr) 1997-07-25 2004-11-03 ALTANA Pharma AG Inhibiteur de la pompe a protons en combinaison therapeutique avec des substances antibacteriennes
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
HUP0002154A3 (en) * 2000-06-06 2002-06-28 Richter Gedeon Vegyeszet Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
DE102005044815A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
EP2603215A4 (fr) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Nouveaux agonistes du recepteur dopaminergique d3 pour traiter la dyskinesie dans la maladie de parkinson
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
AU2014342520B2 (en) 2013-10-28 2019-08-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG39661A1 (en) * 1984-04-13 1986-08-29 Ivanova Antiulcer means
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
US5070101A (en) * 1991-02-14 1991-12-03 Mount Sinai School Of Medicine Of The City University Of New York Method and pharmaceutical composition for the treatment of schizophrenia

Also Published As

Publication number Publication date
CA2145521A1 (fr) 1994-04-14
US5352688A (en) 1994-10-04
US5547969A (en) 1996-08-20
WO1994007490A1 (fr) 1994-04-14
IL107134A0 (en) 1993-12-28
ATE190840T1 (de) 2000-04-15
EP0665749A4 (fr) 1996-04-10
EP0665749B1 (fr) 2000-03-22
DK0665749T3 (da) 2000-08-28
EP0665749A1 (fr) 1995-08-09
AU688739B2 (en) 1998-03-19
DE69328186D1 (de) 2000-04-27
DE69328186T2 (de) 2000-12-21
AU5292993A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
EP0665749B1 (fr) Composition de traitement de la maladie de parkinson
DE69713890T2 (de) Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
CA2336833C (fr) Medicament a effet antidepressif
RU2183128C2 (ru) Фармацевтическая композиция
EP0591434A1 (fr) Methodes et compositions pour le traitement des vomissements, de la nausee et d'autres troubles faisant appel a l'ondansetron optiquement pur r(+)
WO2000002555A1 (fr) Procedes et compositions pour le traitement de la leucemie lymphocitaire chronique
KR20050085681A (ko) 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
KR930007252B1 (ko) 우울증 치료용 약학조성물
KR100761774B1 (ko) 프라미펙솔의 하지 불안 증후군 치료 용도
EP1267849B1 (fr) Substances diminuant la reapparition de l'usage de drogues
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
KR101016927B1 (ko) 알츠하이머 질환의 치료용 ｎｍｄａ 길항제 및 아세틸콜린에스테라제 억제제의 조합물
KR20000029647A (ko) 양극성장애의치료방법
JP3587851B2 (ja) Ｔｎｆ誘発病状の治療におけるベンジダミンの使用
EP0591395A1 (fr) Methodes et compositions pour le traitement des vomissements, de la nausee et d'autres troubles faisant appel a l'ondansetron optiquement pur s(-)
JP2003226642A (ja) 眼疾患予防及び／又は治療薬
EP0821958A2 (fr) Utilisation de la 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tétrahydro-1-méthylpyridine (xanoméline) pour traiter l'agressivité excessive
EP0966286B1 (fr) Attenuation de la tolerance aux opioides par inhibition des mecanismes d'action de la monoxyde d'azote synthetase inductible, dans le traitement de la douleur
CZ20021629A3 (cs) Farmaceutický prostředek
JPH02223523A (ja) 不安及び不眠症の治療のための薬剤
JP2000212091A (ja) 消化管機能異常治療剤
RU2007124557A (ru) Применение отдельных соединений для защиты нейронов и олигодендроцитов при лечении рассеянного склероза
WO1998003201A1 (fr) Nouvelles compositions medicinales a usage therapeutique

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
RH1 Patent not in force